An interventional study of More plant-based protein intake during weight loss in Obesity, sponsored by Amsterdam University of Applied Sciences. Recruiting at 1 site in Netherlands. Open to participants aged 55 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by Amsterdam University of Applied Sciences · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 248 studies in Obesity with a site in Netherlands — 43 open to participants now, 55 under way, 14 of them phase 3. Obesity · Netherlands.
Among the 248 studies in Obesity with a site in Netherlands, this one is the 55th largest by planned enrollment of the 211 interventional ones that give a count, is one of 10 that started in 2024, is one of 128 with no phase, reaches primary completion later than 18 of the 54 other live ones, and was the 228th registered.
11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.
Browse Obesity studies →43 of the 248 studies in Obesity with a site in Netherlands are open now. Recruiting first, the newest first:
Radboud University Medical Center · Sites in Netherlands
Ages 18+
Novo Nordisk A/S · Sites in Netherlands, United States, Belgium and 7 more countries
Ages 18+
Novo Nordisk A/S · Sites in Netherlands, Denmark
Ages 18+
Novo Nordisk A/S · Sites in Netherlands
Ages 18–65 · Healthy volunteers
Novo Nordisk A/S · Sites in Netherlands, United States, Argentina and 16 more countries
Ages 18+
A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →
Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.
This study: 55 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
248 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 23 · Phase 3 38 · Phase 4 13
First in 2001; this study’s year is marked. 10 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is above the median of 67 across 9,043 interventional studies indexed under Obesity.
Median enrollment 58 across the 211 interventional studies, 132 across the 37 observational. Of the 170 that completed or were terminated, 21 (12%) have results posted.
This tab as a report to print or save as PDF → With an account.
68 of 248 have an industry lead sponsor. The 10 most frequent:
Amsterdam University of Applied Sciences is the lead sponsor of 6 studies on the registry; 3 are open to participants now.
Amsterdam University of Applied Sciences has 2 studies filed under Obesity — fewer than ten, so there is no comparison to draw.
19 of the studies in Obesity with a site in Netherlands that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05556512Phase 3Eli Lilly and CompanyA Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity | 2027-10 |
| NCT07463196AC Immune SAA Study Investigating the Safety, Absorption, Elimination, and the Effect on the Immune System of ACI-19764 in Healthy Participants and in Participants With Cardiovascular Risk Factors | 2026-12 |
| NCT06982131Hoffmann-La RocheA Study Investigating the Safety of RO7795081 and the Effect of RO7795081 on How the Body Processes Pitavastatin and Rosuvastatin in Otherwise Healthy Overweight or Obese Adult Participants | 2026-12-07 |
| NCT06137261Franciscus GasthuisScreening Adults With Obesity to Reduce Heart Failure Events | 2026-12-08 |
| NCT05359887University Medical Center GroningenPET-study on the Role of the Reward System in Weight Loss After Bariatric Surgery | 2026-12-31 |
Add all 19 to your calendar (.ics) → With an account.
Among the 248 studies in Obesity with a site in Netherlands, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objective of the 2EAT RCT is to investigate whether a shift towards more plant-based (≥60% with a minimum of 50%) protein intake can be achieved in an energy restricted diet for three and six months in older adults (55+) with obesity.
The 2EAT researchers developed a new dietary counseling plan for six months. This includes four individual consultations, five group meetings and three 24h-recalls. In these six months, participants receive dietary counseling focused on energy restriction (-500 kcal), higher protein intake (aim towards 1.2 g/kg/d, minimum of 0.8 g/kg/d). Participants are randomly allocated either to the more plant-based diet (≥60%) or the more animal-based diet (≥60%). At the start of the intervention, participants are provided with a workbook and recipe book.
Secondary objectives are to assess the effect after three and six months 2EAT dietary treatment on 1) weight loss and 2) skeletal muscle mass. Exploratory objectives are to assess the effect after three and six months 2EAT dietary treatment on 1) physical health outcomes (muscle mass and physical performance), 2) body composition, 3) metabolic blood parameters, 4) vitality and quality of life, 5) nutritional intake, 6) behavioral changes, 7) evaluate the process of the dietary treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The health conditions below will be assessed by the study physician. When a condition interferes the dietary treatment or if the diet worsens the participants health it counts as exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive dietary counseling for six months focusing on 1) more plant-based protein (≥60%), 2) higher protein intake (aim 1.2 g/kg/d, minimum 0.8 g/kg/d) and 3) energy restriction (-500 kcal).
Behavioral: More plant-based protein intake during weight loss
Participants receive dietary counseling for six months focusing on 1) more animal-based protein (≥60%), 2) higher protein intake (aim 1.2 g/kg/d, minimum 0.8 g/kg/d) and 3) energy restriction (-500 kcal).
Behavioral: More plant-based protein intake during weight loss
Participants receive dietary counseling for six months focusing on 1) energy restriction (-500 kcal), 2) higher protein intake (aim 1.2 g/kg/d, minimum 0.8 g/kg/d) and according to their assigned diet, either 3) more plant-based protein (≥60%) or more animal-based protein (≥60%).
Feasibility of high plant-based protein intake while simultaneously striving for weight loss and increased protein intake
Three-day food record (plant protein intake as part of total protein intake; g/day)
Time frame: At baseline (week 0), in week 13 (halfway), in week 26 (end), and optional follow-up (week 52)
Feasibility of a weight loss diet during a more plant-based, higher protein intake
Three-day food record on energy (kcal/day)
Time frame: At baseline (week 0), in week 13 (halfway), in week 26 (end), and optional follow-up (week 52)
Feasibility of an increased protein intake during a more plant-based protein, weight loss diet
Three-day food record on protein intake (g/day)
Time frame: At baseline (week 0), in week 13 (halfway), in week 26 (end), and optional follow-up (week 52)
Effect of 2EAT dietary treatment on weight loss
Body weight in kg (calibrated weighing scales)
Time frame: At baseline (week 0), in week 13 (halfway), in week 26 (end), and optional follow-up (week 52)
Effect of 2EAT dietary treatment on skeletal muscle mass
Skeletal muscle mass (appendicular lean soft tissue (ALST) in kg) via a DXA-scan
Time frame: At baseline (week 0), in week 13 (halfway), in week 26 (end), and optional follow-up (week 52)
Effect of 2EAT dietary treatment on physical performance
Short Physical Performance Battery (SPPB). Minimum value: 0; Maximum value 12. Score 0-3: severe limitations; score 4-9: intermediate limitations; score 9-12: normal function.
Time frame: At baseline (week 0), in week 13 (halfway), in week 26 (end), and optional follow-up (week 52)
Effect of 2EAT dietary treatment on walking distance
400 meter walk test (MWT) in seconds (s)
Time frame: At baseline (week 0), in week 13 (halfway), in week 26 (end), and optional follow-up (week 52)
Effect of 2EAT dietary treatment on muscle strength
Hand Grip Strength (kg)
Time frame: At baseline (week 0), in week 13 (halfway), in week 26 (end), and optional follow-up (week 52)
Effect of 2EAT dietary treatment on fat free mass
Fat free mass (in kg) via BODPOD air displacement plethysmograph
Time frame: At baseline (week 0), in week 13 (halfway), in week 26 (end), and optional follow-up (week 52)
Effect of 2EAT dietary treatment on LDL-cholesterol
Serum LDL-cholesterol (mmol/L)
Time frame: At baseline (week 0), in week 12 (halfway), in week 26 (end)
Effect of 2EAT dietary treatment on HDL-cholesterol
Serum HDL-cholesterol (mmol/L)
Time frame: At baseline (week 0), in week 12 (halfway), in week 26 (end)
Effect of 2EAT dietary treatment on total cholesterol
Serum total cholesterol mmol/L)
Time frame: At baseline (week 0), in week 12 (halfway), in week 26 (end)
Effect of 2EAT dietary treatment on triglycerides
Serum triglycerides (mmol/L)
Time frame: At baseline (week 0), in week 12 (halfway), in week 26 (end)
Effect of 2EAT dietary treatment on long-term blood glucose concentration
HbA1c (mmol/mol)
Time frame: At baseline (week 0), in week 12 (halfway), in week 26 (end)
Effect of 2EAT dietary treatment on insulin resistance
Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) (values \>2 indicate insulin resistance)
Time frame: At baseline (week 0), in week 12 (halfway), in week 26 (end)
Effect of 2EAT dietary treatment on inflammation
High sensitivity CRP (mg/L)
Time frame: At baseline (week 0), in week 12 (halfway), in week 26 (end)
Effect of 2EAT dietary treatment on vitamin B12 levels
Serum vitamin B12 (pg/mL)
Time frame: At baseline (week 0), in week 12 (halfway), in week 26 (end)
Effect of 2EAT dietary treatment on body iron stores
Serum ferritin (mcg/L)
Time frame: At baseline (week 0), in week 12 (halfway), in week 26 (end)
Effect of 2EAT dietary treatment on blood haemoglobin concentration
Blood haemoglobin (mmol/L)
Time frame: At baseline (week 0), in week 12 (halfway), in week 26 (end)
Effect of 2EAT dietary treatment on vitality
De Nederlandse vitaliteitsmeter (VITA-16 questionnaire). Minimum value: 0; Maximum value 7. Higher scores indicate more vitality.
Time frame: At baseline (week 0), in week 13 (halfway), in week 26 (end), and optional follow-up (week 52)
Effect of 2EAT dietary treatment on quality of life
Short-Form-36 questionnaire (SF-36) Minimum value: 0; Maximum value 100. Higher scores indicate better health-related quality of life. A score of 0 indicates very poor health-related quality of life, whereas a score of 100 indicates a very good health-related quality of life.
Time frame: At baseline (week 0), in week 13 (halfway), in week 26 (end), and optional follow-up (week 52)
Effect of 2EAT dietary treatment on carbohydrate intake
Three-day food record on carbohydrate (g/day)
Time frame: At baseline (week 0), in week 13 (halfway), in week 26 (end), and optional follow-up (week 52)
Effect of 2EAT dietary treatment on fat intake
Three-day food record on fat (g/day)
Time frame: At baseline (week 0), in week 13 (halfway), in week 26 (end), and optional follow-up (week 52)
Effect of 2EAT dietary treatment on saturated fat intake
Three-day food record on saturated fat (g/day)
Time frame: At baseline (week 0), in week 13 (halfway), in week 26 (end), and optional follow-up (week 52)
Effect of 2EAT dietary treatment on fiber intake
Three-day food record on fiber (g/day)
Time frame: At baseline (week 0), in week 13 (halfway), in week 26 (end), and optional follow-up (week 52)
Effect of 2EAT dietary treatment on calcium intake
Three-day food record on calcium (mg/day)
Time frame: At baseline (week 0), in week 13 (halfway), in week 26 (end), and optional follow-up (week 52)
Effect of 2EAT dietary treatment on iron intake
Three-day food record on iron (mg/day)
Time frame: At baseline (week 0), in week 13 (halfway), in week 26 (end), and optional follow-up (week 52)
Effect of 2EAT dietary treatment on zinc intake
Three-day food record on zinc (mg/day)
Time frame: At baseline (week 0), in week 13 (halfway), in week 26 (end), and optional follow-up (week 52)
Effect of 2EAT dietary treatment on magnesium intake
Three-day food record on magnesium (mg/day)
Time frame: At baseline (week 0), in week 13 (halfway), in week 26 (end), and optional follow-up (week 52)
Effect of 2EAT dietary treatment on selenium intake
Three-day food record on selenium (mcg/day)
Time frame: At baseline (week 0), in week 13 (halfway), in week 26 (end), and optional follow-up (week 52)
Effect of 2EAT dietary treatment on vitamin B1 intake
Three-day food record on vitamin B1 (mg/day)
Time frame: At baseline (week 0), in week 13 (halfway), in week 26 (end), and optional follow-up (week 52)
Effect of 2EAT dietary treatment on vitamin B2 intake
Three-day food record on vitamin B2 (mg/day)
Time frame: At baseline (week 0), in week 13 (halfway), in week 26 (end), and optional follow-up (week 52)
Effect of 2EAT dietary treatment on vitamin B6 intake
Three-day food record on vitamin B6 (mcg/day)
Time frame: At baseline (week 0), in week 13 (halfway), in week 26 (end), and optional follow-up (week 52)
Effect of 2EAT dietary treatment on folic acid intake
Three-day food record on folic acid (mcg/day)
Time frame: At baseline (week 0), in week 13 (halfway), in week 26 (end), and optional follow-up (week 52)
Effect of 2EAT dietary treatment on vitamin B12 intake
Three-day food record on vitamin B12 (mcg/day)
Time frame: At baseline (week 0), in week 13 (halfway), in week 26 (end), and optional follow-up (week 52)
Effect of 2EAT dietary treatment on vitamin C intake
Three-day food record on vitamin C (mg/day)
Time frame: At baseline (week 0), in week 13 (halfway), in week 26 (end), and optional follow-up (week 52)
Effect of 2EAT dietary treatment on vitamin D intake
Three-day food record on vitamin D (mcg/day)
Time frame: At baseline (week 0), in week 13 (halfway), in week 26 (end), and optional follow-up (week 52)
Effect of 2EAT dietary treatment on vitamin E intake
Three-day food record on vitamin E (mg/day)
Time frame: At baseline (week 0), in week 13 (halfway), in week 26 (end), and optional follow-up (week 52)
Effect of 2EAT dietary treatment on behavior, dimension "diffuse emotions"
Nederlandse Vragenlijst Eetgedrag (NVE) questionnaire on dimension "diffuse emotions". Sum questions 3, 8, 10, 28 and divide by 4. Minimal score: 0; maximal score: 5. A score of 5 means the individual has a lot of diffuse emotions, a score of 0 means no diffuse emotions.
Time frame: At baseline (week 0), in week 13 (halfway), in week 26 (end), and optional follow-up (week 52)
Effect of 2EAT dietary treatment on behavior, dimension "clearly described emotions"
Nederlandse Vragenlijst Eetgedrag (NVE) questionnaire on dimension "clearly described emotions". Sum questions 1, 5, 13, 16, 20, 23, 25, 30, 32 and divide by 9. Minimal score: 0; maximal score: 5. A score of 5 means the individual has clearly described emotions, a score of 0 means no clearly described emotions.
Time frame: At baseline (week 0), in week 13 (halfway), in week 26 (end), and optional follow-up (week 52)
Effect of 2EAT dietary treatment on behavior, dimension "emotional eating"
Nederlandse Vragenlijst Eetgedrag (NVE) questionnaire dimension "emotional eating". Sum questions 1, 3, 5, 8, 10, 13, 16, 20, 23, 25, 28, 30, 32 and divide by 13. Minimal score: 0; maximal score: 5. A score of 5 means the individual is a very emotional eater, a score of 0 means no emotional eating.
Time frame: At baseline (week 0), in week 13 (halfway), in week 26 (end), and optional follow-up (week 52)
Effect of 2EAT dietary treatment on behavior, dimension "external eating"
Nederlandse Vragenlijst Eetgedrag (NVE) questionnaire dimension "external eating". Sum questions 2, 6, 9, 12, 15, 18, 21, 24, 27, 33 and divide by 10. Minimal score: 0; maximal score: 5. A score of 5 means the individual is a very external eater, a score of 0 means no external eating.
Time frame: At baseline (week 0), in week 13 (halfway), in week 26 (end), and optional follow-up (week 52)
Effect of 2EAT dietary treatment on behavior, dimension "diet-oriented eating"
Nederlandse Vragenlijst Eetgedrag (NVE) questionnaire dimension "diet-oriented eating". Sum questions 4, 7, 11, 14, 17, 19, 22, 26, 29, 31 and divide by 10. Minimal score: 0; maximal score: 5. A score of 5 means the individual is a very diet-oriented eater, a score of 0 means no diet-oriented eating.
Time frame: At baseline (week 0), in week 13 (halfway), in week 26 (end), and optional follow-up (week 52)
Process evaluation of the 2EAT dietary treatment
Paper-based questionnaire with open questions
Time frame: At week 26 (end)
End evaluation of the 2EAT dietary treatment
Paper-based questionnaire with open questions
Time frame: Optional follow-up (week 52)
Plan to share: Undecided — Participants have agreed or disagreed to share data later. At this moment it is still undecided whether we will share data.
No publications or documents are linked to this record.
Started Aug 2024 (actual). Primary completion is estimated for Apr 2027, 32 months after the start.
Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 32 months is above that.
Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.
Primary completion moved once since we started tracking on Sep 25, 2026: Oct 2026 → Apr 2027, on Nov 17, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Amsterdam University of Applied Sciences